Multiple Myeloma (Plasma Cell Cancer), Treatment & Drug Global Market Analysis (Size, Market Data, Trends, Growth) -Forecast to 2025

Published On: April 2016

Multiple Myeloma (Plasma Cell Cancer) Article Brief:

This article provides an overview about the global multiple myeloma (plasma cell cancer), treatment & drug market during the forecast period 2016-2027, there by offering insights on key present growth indicators and forecast indicators such as drivers, restrains, opportunities and trends, that are involved in shaping the market.

About Multiple Myeloma:

Multiple Myeloma is the type of the cancer that occurs in the plasma cells. In human body the plasma cells are responsible for producing the antibodies. In myeloma the abnormal plasma cells start accumulating into the bone marrow which hampers production of the regular body cells. Multiple myeloma can be diagnosed through the blood tests (serum protein electrophoresis, serum free kappa/lambda light chain assay), bone marrow examination, urine protein electrophoresis, and X-rays of commonly involved bones.

Multiple Myeloma is one of the most chronic diseases. It is considered as considered to be incurable but treatable. Its intensity can be reduced by steroids, chemotherapy, proteasome inhibitors, immunomodulatory drugs such as thalidomide or lenalidomide, and stem cell transplants.

Multiple Myeloma Market:

In last few years the multiple myeloma market has grown significantly as it had an impressive sale in the years 2013 & 2014 regardless of its relatively low incidence. Multiple Myeloma market is promises the significant revenue as compared with other oncology markets significant developments in the clinical practice. Since the last decade, there have been launches of effectual, treatments and drugs that are priced at premium due to their high cost and patents. These continual processes development in future is expected to drive multiple myeloma market 2023. However, there is still an untapped market potential of developing the treatment that will help to survive the multiple myeloma patients.

Multiple Myeloma Market by Geography:

The myeloma market is expected to be concentrated across the eight major countries such as US, Canada, France, UK, Germany, Spain, Italy, and, Japan. It will be primarily driven due to the rising multiple myeloma prevalence as a cause of the aging population.

This project report provides the market information & market data about the following segments and products:

• Disease Management
  
  
  
  • Treatment Overview  
  
  
  • Diagnosis, By Country           
  
  
  • Clinical Practice for Therapy Type, By Country       
    
    
    
    • Primary Therapy for SCT-Eligible Patients, By Country      
    
    
    • Primary Therapy for Non-SCT Patients, By Country           
    
    
    • Chemotherapy, By Country  
    
    
    • Salvage/Relapse Therapy, Country  
    
    
    • Leading Prescribed Drugs, Country  
    
    
    • Radiation therapy       
    
    
    • Surgery          
    
    
    
    
  
  
  
  


• Chemotherapy Overview
  
  
  
  • Induction chemotherapy
  
  
  • Consolidation chemotherapy
  
  
  • Maintenance therapy
  
  
  
  


• Global Chemotherapy Market By Delivery Type
  
  
  
  • Intravenous (IV)
  
  
  • Swallowed (orally)
  
  
  • Topically
  
  
  • Direct placement
  
  
  
  


• Chemotherapy Market By Class Type
  
  
  
  • Anthracycline Antibiotic         
    
    
    
    • Liposomal doxorubicin (Doxil)           
    
    
    • Doxorubicin (Adriamycin)      
    
    
    
    
  
  
  • Alkylating Agent         
    
    
    
    • Melphalan (Alkeran)  
    
    
    • Cyclophosphamide (Neosar, Cytoxan)         
    
    
    • Vincristine (Oncovin) 
    
    
    • Carmustine (BiCNU) 
    
    
    • Bendamustine (Treanda)       
    
    
    
    
  
  
  • Plant Alkaloid 
    
    
    
    • Etoposide (VP-16/ Toposar, VePesid, Etopophos)   
    
    
    • Vincristine (Oncovin, Vincasar Pfs)  
    
    
    
    
  
  
  • Antiangiogenic Agent 
    
    
    
    • Thalidomide   
    
    
    • Lenalidomide  
    
    
    
    
  
  
  • Others
  
  
  • Histone Deacetylase (HDAC) Inhibitor          
    
    
    
    • Panobinostat  
    
    
    • Velcade (bortezomib)
    
    
    • Dexamethasone        
    
    
    
    
  
  
  • Proteasome Inhibitor  
    
    
    
    • Carfilzomib (Kyprolis)
    
    
    • Ixazomib (Ninlaro)     
    
    
    • Others
    
    
    
    
  
  
  • Antiangiogenic Agent 
    
    
    
    • Lenalidomide (Revlimid)        
    
    
    • Pomalidomide (Pomalyst)     
    
    
    • Thalidomide (Synovir, Thalomid)      
    
    
    • Daratumumab (Darzalex)      
    
    
    • Elotumumab (Empliciti)         
    
    
    
    
  
  
  • Corticosteroid 
  
  
  
  

Every report of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market dynamics which includes trends, drivers, and restraints, opportunities along with the macro economical and governing factors. The report also gives a comprehensive study of the different market segments and regions.